Associations Between Common Polymorphisms of CDKN2B-AS and Susceptibility to ASCVD

Abstract

This meta-analysis was conducted to estimate associations between CDKN2B antisense (CDKN2B-AS) polymorphisms and susceptibility to atherosclerotic cardio-cerebral vascular diseases (ASCVD). A systematic literature research of PubMed, Medline, Web of Science, Embase, and CNKI was performed to identify eligible studies. Overall, 34 studies were included for meta-analyses. Pooled overall analyses showed that rs1333040, rs1333049, rs2383206, and rs2383207 polymorphisms were associated with susceptibility to ASCVD in the whole population. Further analyses by ethnicity revealed that all investigated polymorphisms were associated with susceptibility to ASCVD in East Asians. Moreover, rs2383206, rs2383207, rs10757274, and rs10757278 polymorphisms were associated with susceptibility to ASCVD in West Asians, while rs2383206, rs10757274, and rs10757278 were associated with susceptibility to ASCVD in Caucasians. When we stratified eligible studies by type of disease, positive results were found for all investigated polymorphisms in patients with coronary artery disease (CAD) or myocardial infarction, whereas positive results were only detected for rs2383206 and rs10757274 polymorphisms in patients with ischemic stroke (IS). Our findings suggest that rs1333040, rs1333049, rs2383206, rs2383207, rs10757274, and rs10757278 polymorphisms might serve as genetic biomarkers of CAD, and rs2383206 and rs10757274 polymorphisms might serve as genetic biomarkers of IS.

Keywords

gene polymorphisms atherosclerotic cardio-cerebral vascular diseases (ASCVD)meta-analysis

Get full access to this article

View all access options for this article.

References

Rognoni

Cavallino

Veia

, et al. Pathophysiology of atherosclerotic plaque development. Cardiovasc Hematol Agents Med Chem. 2015;13:10–3.

Libby

Ridker

Hansson

. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25.

Newsom

. Primary prevention of atherosclerotic cardiovascular disease: controversies and clinical considerations. Ann Pharmacother. 2015;49:484–93.

Lusis

Fogelman

Fonarow

. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation. 2004;110:1868–73.

Mighter

Erdmann

Schunkert

. Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol. 2007;96:1–7.

Lloyd-Jones

Nam

D’Agostino

Sr , et al. Parental cardiovascular disease as a susceptibility factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291:2204–11.

Dai

Wiernek

Evans

Runge

. Genetics of coronary artery disease and myocardial infarction. World J Cardiol. 2016;8:1–23.

Kessler

Vilne

Schunkert

. The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med. 2016;8:688–701.

Morrison

Bare

Chambless

, et al. Prediction of coronary heart disease susceptibility using a genetic susceptibility score: the atherosclerosis susceptibility in communities study. Am J Epidemiol. 2007;166:28–35.

10.

Thanassoulis

Peloso

Pencina

, et al. A genetic susceptibility score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham Heart Study. Circ Cardiovasc Genet. 2012;5:113–21.

11.

Peschansky

Wahlestedt

. Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics. 2014;9:3–12.

12.

Esteller

. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.

13.

Congrains

Kamide

Oguro

, et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis. 2012;220:449–55.

14.

Cunnington

Keavney

. Genetic mechanisms mediating atherosclerosis susceptibility at the chromosome 9p21 locus. Curr Atheroscler Rep. 2011;13:193–201.

15.

Moher

Liberati

Tetzlaff

Altman

, PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.

16.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.

17.

Ahmed

Ali

Riaz

, et al. Association of ANRIL polymorphism (rs1333049: C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia. Gene. 2013;515:416–20.

18.

Xie

Shi

Liu

. The roles of TLR gene variants in atherosclerosis: a systematic review and meta-analysis of 35,317 subjects. Scand J Immunol. 2017;86:50–8.

19.

Shi

Xie

Jia

. Associations of insulin receptor and insulin receptor substrates genetic variants with polycystic ovary syndrome: a systematic review and meta-analysis. J Obstet Gynaecol Res. 2016;42:844–54.

20.

Xie

Shi

Xun

Rao

. Endothelial nitric oxide synthase gene single nucleotide variants and the susceptibility of hypertension: a meta-analysis involving 63,258 subjects. Clin Exp Hypertens. 2017;39:175–82.

21.

Zhu

Zheng

. Association between SERT insertion/deletion polymorphism and the susceptibility of irritable bowel syndrome: a meta-analysis based on 7039 subjects. Gene. 2018;679:133–7.

22.

Sun

Jin

Qiao

. Associations of tumor necrosis factor-α variants with the susceptibility of asthma: a meta-analysis. Exp Mol Pathol. 2018;105:411–6.